This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In recent years, transcatheter aortic valve replacement (TAVR) has emerged as a popular alternative to the traditional surgical aortic valve replacement. These risks, combined with advanced age, significant co-morbidities, and a severely calcified small aortic annulus, supported the choice of TAVR with a self-expanding Acurate Neo2 valve.
Background and aims Randomised controlled trials comparing transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) were performed in highly selected populations and data regarding long-term secondary complications beyond mortality are scarce. Results The study included 9355 SAVR and 2641 TAVR patients.
Objective Postprocedural ischaemic and bleeding risks after transcatheter aortic valve replacement (TAVR) remain a major concern. We aimed to assess the accuracy of percutaneous coronary intervention (PCI)-derived models and the performance of a recalibrated model that included variables more applicable to TAVR.
ET Murphy Ballroom 4 ACC.24 24 planners note that attendees can gain insights from key clinical trials presented at ACC.24 24 and how those may impact clinical practice and patient care in this deep dive clinical trial session.
Background:Atherosclerotic cardiovascular disease (ASCVD) is highly prevalent in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR). Exposure of interest was PVD. Primary outcome was all-cause mortality.
The primary safety end point is a composite of cardiac death, myocardialinfarction, and ischemic stroke at 1 year. The primary efficacy end point is the incidence of bleeding events, defined by the VARC3 (Valve Academic Research Consortium3) criteria, at 1year postrandomization.
This typically occurs after an inferior posterior myocardialinfarction, drug-induced CHB. Currently, with the arrrival of TAVR, CHB has beceome a glamorous complication and is getting wider attention.
EMPACT-MI 1 ( NCT04509674 ) studied the effects of empagliflozin in patients who have experienced myocardialinfarction (MI). SMART 4 ( NCT04722250 ) studied patients with severe aortic stenosis and a small aortic annulus who underwent transcatheter aortic valve replacement (TAVR). Here is our curated list of the top sessions.
myocardialinfarction), arrhythmias, valvular pathology, shunts, or outflow obstructions. 6,7 Surgical repair of AS, by either TAVR or SAVR, is the definitive treatment for this condition. Fundamentally, cardiogenic shock is an issue of decreased cardiac output.
Comparisons were made between men and women and type of valve implant (ie, surgical implantation with a mechanical (mSAVR) (n=1 966) or biological valve (bioSAVR) (n=9 801)) or by a transcatheter approach (TAVR) (n=2 356). In the TAVR cohort, men suffered a higher risk of death (HR: 1.24; 95% CI: 1.07 to 1.82, p=0.047).
Scott Rankin The Impact of Mitral Disease Etiology on Operative Mortality After Mitral Valve Operations The Annals of Thoracic Surgery November 2018 Alice Wang Robotic Mitral Valve Repair in Older Individuals: An Analysis of The Society of Thoracic Surgeons Database The Annals of Thoracic Surgery November 2018 Mohamad Alaeddine Aortic clamping strategy (..)
Scott Rankin The Impact of Mitral Disease Etiology on Operative Mortality After Mitral Valve Operations The Annals of Thoracic Surgery November 2018 Alice Wang 1 Robotic Mitral Valve Repair in Older Individuals: An Analysis of The Society of Thoracic Surgeons Database The Annals of Thoracic Surgery November 2018 Mohamad Alaeddine 1 Aortic clamping (..)
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
52 
Let's personalize your content